— Know what they know.
Not Investment Advice

KLRS NASDAQ

Kalaris Therapeutics Inc
1W: -7.5% 1M: -30.8% 3M: -41.9% YTD: -67.5% 1Y: -55.5%
$2.70
-0.15 (-5.26%)
 
Weekly Expected Move ±5.8%
$2 $3 $3 $3 $3
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Sell · Power 27 · $58.9M mcap · 7M float · 2.81% daily turnover · Short 49% of daily vol

Balance Sheet Trends

Total Assets
$122M +2.7% ▲
5Y CAGR: -20.0%
Total Liabilities
$43M +719.3% ▲
5Y CAGR: +19.3%
Shareholders Equity
$79M -30.4% ▼
5Y CAGR: -25.9%
Cash & Investments
$118M -0.3% ▼
5Y CAGR: -19.8%
Total Debt
$1M +0.0% ▲
5Y CAGR: -30.1%
Net Debt
-$97M +18.3% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$202M$3M$3M$118M$98M
Short-Term Investments$46M$0$0$0$20M
Cash & ST Investments$248M$3M$3M$118M$118M
Net Receivables$50K$0$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$5M$0$0$257K$78K
Total Current Assets$253M$4M$3M$119M$119M
Property, Plant & Equip.$31M$0$0$0$1M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$852K$0$0$0$499K
Other Non-Current Assets$1M$0$0$0$953K
Total Non-Current Assets$33M$0$0$0$3M
Total Assets$287M$4M$3M$119M$122M
— Liabilities —
Accounts Payable$8M$3M$2M$247K$1M
Short-Term Debt$7M$0$0$0$316K
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$15M$296K$540K$2M$7M
Total Current Liabilities$38M$6M$4M$5M$10M
Long-Term Debt$0$3M$0$0$0
Other Non-Current Liab.$0$25M$44M$0$32M
Total Non-Current Liabilities$23M$28M$44M$0$33M
Total Liabilities$61M$34M$48M$5M$43M
— Equity —
Common Stock$7K$0$0$0$2K
Retained Earnings-$297M-$33M-$47M-$715M-$160M
Accumulated OCI-$155K$0$0-$135K$6K
Total Stockholders Equity$225M-$30M-$45M$113M$79M
Total Liabilities & Equity$287M$4M$3M$119M$122M
— Key Metrics —
Total Debt$30M$3M$0$0$1M
Net Debt-$172M$194K-$3M-$118M-$97M
Total Investments$47M$0$0$0$20M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms